Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2014 | 4 | 4 | 6-18

Article title

Constriction of Fetal Ductus Arteriosus and Maternal Intake of Polyphenol-Rich Foods



Title variants

Languages of publication



Fetal ductal constriction is a potentially severe functional alteration, often causing right ventricular overload and insufficiency, tricuspid regurgitation and neonatal pulmonary hypertension. Classically, maternal administration of indomethacin and/or other nonsteroidal antiinflammatory drugs interfere in prostaglandin metabolism, leading to ductal constriction. However, many cases of fetal ductal constriction, as well as of persistent neonatal pulmonary artery hypertension, remain without an established etiology, being referred as “idiopathic”. In recent years, a growing body of evidences has shown that herbs, fruits, nuts, and a wide diversity of substances commonly used in daily diet, because of their high content of polyphenols, have definitive effects upon the metabolic pathway of inflammation, with consequent inhibition of prostaglandins synthesis. This anti-inflammatory action of polyphenols, when ingested during the third trimester of pregnancy, may interfere with the dynamics of fetal ductus arteriosus flow and cause ductal constriction. This review has the purpose to approach these new evidences, which may influence dietary orientation during pregnancy.









Physical description


1 - 12 - 2014
27 - 7 - 2014
29 - 7 - 2014
30 - 12 - 2015


  • Fetal Cardiology Unit, Institute of Cardiology, Porto Alegre, Brazil


  • 1. Bergwerff M, DeRuiter MC and Gittenberger-de Groot AC.: Comparative anatomy and ontogeny of the ductus arteriosus, a vascular outsider. Anat Embryol (Berl) 1999, 200 (6): 559-71[Crossref]
  • 2. Ho S.Y. and Anderson RH.: Anatomical closure of the ductus arteriosus: a study in 35 specimens. J Anat, 1979, 128 (Pt 4): 829-36
  • 3. Yajima I, et al.: A subpopulation of smooth muscle cells, derived from melanocyte-competent precursors, prevents patent ductus arteriosus. PLoS One, 2013, 8 (1): e53183[Crossref]
  • 4. Tada T, et al.: Human ductus arteriosus. A histological study on the relation between ductal maturation and gestational age. Acta Pathol Jpn 1985, 35 (1) : 23-34
  • 5. Slomp J, et al.: Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening. An immunohistochemical study of changes in extracellular matrix components. Atherosclerosis 1992, 93 (1-2): 25-39[Crossref]
  • 6. de Reeder EG, et al.: Distribution of prostacyclin synthase, 6-ketoprostaglandin F1 alpha, and 15-hydroxy-prostaglandin dehydrogenase in the normal and persistent ductus arteriosus of the dog. Am J Pathol 1989, 135 (5): 881-7
  • 7. Majed BH, .: Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacological Reviews, 2012
  • 8. Slomp J., et al.: Differentiation, dedifferentiation, and apoptosis of smooth muscle cells during the development of the human ductus arteriosus. Arterioscler Thromb Vasc Biol, 1997. 17(5): 1003-9[Crossref]
  • 9. Hong Z., et al.: Role of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission in oxygen sensing and constriction of the ductus arteriosus. Circ Res, 2013, 112 (5): 802-15[Crossref]
  • 10. Obladen M.: History of the ductus arteriosus: 1. Anatomy and spontaneous closure. Neonatology 2011, 99 (2): 83-9[Crossref]
  • 11. Coceani F.: Oxygen sensing in the ductus arteriosus: endothelin still a player. Circ Res 2013, 112 (11): e154[Crossref]
  • 12. Michelakis ED, et al.,: Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells. J Mol Cell Cardiol 2004, 37 (6): 1119-36
  • 13. Coceani F. and B. Baragatti.: Mechanisms for ductus arteriosus closure. Semin Perinatol 2012, 36 (2): 92-7[Crossref]
  • 14. Heymann MA and Rudolph AM.: Control of the ductus arteriosus. Physiol Rev 1975, 55 (1): 62-78
  • 15. Brezinka C, Gittenberger-de Groot AC and Wladimiroff JW.: The fetal ductus arteriosus, a review. Zentralbl Gynakol 1993, 115 (10): 423-32
  • 16. Tynan M.: The ductus arteriosus and its closure. N Engl J Med 1993, 329 (21): 1570-2
  • 17. Stoller JZ, et al.: Current Perspectives on Pathobiology of the Ductus Arteriosus. J Clin Exp Cardiolog 2001, 8(1)
  • 18. Levin M, et al.: ATP depletion and cell death in the neonatal lamb ductus arteriosus. Pediatr Res 2005, 57(6): 801-5[Crossref]
  • 19. Tarcan A.: et al.: Persistent pulmonary hypertension in a premature newborn after 16 hours of antenatal indomethacin exposure. J Perinat Med, 2004. 32 (1): 98-9
  • 20. Takami T, Momma K and Imamura S.: Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. Circ J 2005, 69 (3): 354-8[Crossref]
  • 21. Momma K, et al.: In vivo constriction of the fetal and neonatal ductus arteriosus by a prostanoid EP4-receptor antagonist in rats. Pediatr Res 2005, 58 (5): 971-5[Crossref]
  • 22. Ichikawa Y, et al.: Inhibition of phosphodiesterase type 3 dilates the rat ductus arteriosus without inducing intimal thickening. Circ J, 2012, 76 (10): 2456-64[Crossref]
  • 23. Toyoshima K., et al.: In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats. Biol Neonate 2006, 89 (4): 251-6
  • 24. Coceani F et al.: Deletion of the endothelin-A-receptor suppresses oxygeninduced constriction but not postnatal closure of the ductus arteriosus. J Cardiovasc Pharmacol, 2000. 36 (5 Suppl 1): S75-7[Crossref]
  • 25. Baragatti B, et al.: Cytochrome P-450 3A13 and endothelin jointly mediate ductus arteriosus constriction to oxygen in mice. Am J Physiol Heart Circ Physiol 2011, 300 (3): H892-901
  • 26. Momma KT, Nakanishi and Imamura S. .: Inhibition of in vivo constriction of fetal ductus arteriosus by endothelin receptor blockade in rats. Pediatr Res 2003, 53 (3): 479-85[Crossref]
  • 27. Takizawa, T, et al.: Effects of TAK-044, a nonselective endothelin receptor antagonist, on the spontaneous and indomethacin- or methylene blue-induced constriction of the ductus arteriosus in rats. J Vet Med Sci 2000, 62 (5): 505-9[Crossref]
  • 28. Norton ME.: Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology 199, 56 (4): 282-92[Crossref]
  • 29. Sharpe GL, Larsson KS and Thalme B: Studies on closure of the ductus arteriosus. XII. In utero effect of indomethacin and sodium salicylate in rats and rabbits. Prostaglandins 1975, 9 (4): 585-96[Crossref]
  • 30. Levy R, et al.: Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. Am J Perinatol 1999, 16 (8): 379-83[Crossref]
  • 31. Dudley DK and Hardie MJ.: Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol 1985, 151 (2): 181-4[Crossref]
  • 32. Gordon MC and Samuels P.: Indomethacin. Clin Obstet Gynecol 1995, 38(4): 697-705[Crossref]
  • 33. Rasanen J and Jouppila P.: Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am J Obstet Gynecol 1995, 173 (1): 20-5[Crossref]
  • 34. Moise KJ, Jr, et al.: Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988, 319 (6): 327-31[Crossref]
  • 35. Vermillion ST, et al.: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997, 177 (2): 256-9[Crossref]
  • 36. Paladini, D, Marasini M and Volpe P.: Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet Gynecol 2005, 25 (4): 357-61[Crossref]
  • 37. Auer M, et al.: Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application. Ultrasound Obstet Gynecol 2004, 23 (5): 513-6[Crossref]
  • 38. Schiessl B, et al.: Prenatal constriction of the fetal ductus arteriosus--related to maternal pain medication? Z Geburtshilfe Neonatol 2005, 209 (2): 65-8[Crossref]
  • 39. Toyoshima K, et al.: Constriction of the ductus arteriosus by selective inhibition of cyclooxygenase-1 and -2 in near-term and preterm fetal rats. Prostaglandins Other Lipid Mediat 2006, 79 (1-2): 34-42[Crossref]
  • 40. Clyman RI, et al.: Glucocorticoids alter the sensitivity of the lamb ductus arteriosus to prostaglandin E2. J Pediatr 1981, 98 (1): 126-8 [Crossref]
  • 41. Karadas B, et al.: Comparison of effects of cyclooxygenase inhibitors on myometrial contraction and constriction of ductus arteriosus in rats. Eur J Pharmacol 2004, 485 (1-3): 289-98[Crossref]
  • 42. Takahashi Y, et al.: Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 2000, 278 (6): R1496-505
  • 43. Clyman RI, et al.: Prenatal administration of betamethasone for prevention of patient ductus arteriosus. J Pediatr 1981, 98 (1): 123-6[Crossref]
  • 44. Azancot-Benisty A, et al.: Constriction of the fetal ductus arteriosus during prenatal betamethasone therapy. Obstet Gynecol 1995, 85 (5 Pt 2): 874-6[Crossref]
  • 45. Hassid A.: Regulation of prostaglandin biosynthesis in cultured cells. Am J Physiol 1982, 243 (5): C205-11
  • 46. Momma K, Nishihara S, and Ota Y.: Constriction of the fetal ductus arteriosus by glucocorticoid hormones. Pediatr Res 1981, 15 (1): 19-21[Crossref]
  • 47. Wu GR, et al.: The effect of vitamin A on contraction of the ductus arteriosus in fetal rat. Pediatr Res 2001, 49 (6): 747-54[Crossref]
  • 48. Chen JX, et al.: Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus. Pediatr Res 2012, 72 (2): 122-8[Crossref]
  • 49. Fan F, et al.: Effect of PGE2 on DA tone by EP4 modulating Kv channels with different oxygen tension between preterm and term. International Journal of Cardiology, 2011 147:58-65, 2011
  • 50. Keller RL, et al.: Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns. Pediatr Res 2005, 58 (6): 1216-21[Crossref]
  • 51. Takizawa T, Kihara T and Kamata A.: Increased constriction of the ductus arteriosus with combined administration of indomethacin and L-NAME in fetal rats. Biol Neonate 2001, 80 (1): 64-7[Crossref]
  • 52. Reese J, et.al.: Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. Prostaglandins & Other Lipid Mediators 2009, 88: 89-96[Crossref]
  • 53. Hsu JH, et al.: Nitric oxide alterations following acute ductal constriction in the fetal lamb: a role for superoxide. Am J Physiol Lung Cell Mol Physiol 2010, 298 (6): 880-7[Crossref]
  • 54. Kajimoto H, et al.: Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation 2007, 115 (13): 1777-88[Crossref]
  • 55. Vogel M, et.al.: Reversible ductus arteriosus constriction due to maternal indomethacin after fetal intervention for hypoplastic left heart syndrome with intact/restrictive atrial septum. Fetal Diagnosis and Therapy 2011, 27: 40-45
  • 56. Moise KJ, Jr, et al.: Placental transfer of indomethacin in the human pregnancy. Am J Obstet Gynecol 1990, 162 (2): 549-54[Crossref]
  • 57. Hallak M, et al.: Indomethacin for preterm labor: fetal toxicity in a dizygotic twin gestation. Obstet Gynecol 1991, 78 (5 Pt 2): 911-3
  • 58. Moise KJ, Jr.: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993, 168 (5): 1350-3[Crossref]
  • 59. Koren G, et al.: Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006, 40 (5): 824-9[Crossref]
  • 60. Momma K, Hagiwara H and Konishi T.: Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins 1984, 28(4): 527-36[Crossref]
  • 61. Cooper CL and Malik KU.: Effect of glucocorticoids on vascular reactivity to vasoactive hormones in rat isolated kidney: lack of relationship to prostaglandins. Br J Pharmacol 1984, 82 (3): 679-88[Crossref]
  • 62. Wasserstrum N, et al.: Betamethasone and the human fetal ductus arteriosus. Obstet Gynecol 1989, 74(6): 897-900
  • 63. Mushiake K, et. al.: Severe heart failure due to ductal constriction caused by maternal indomethacin. Pediatrics International 2002, 44:174-176, [Crossref]
  • 64. Eronen M, et al.: The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study. Am J Obstet Gynecol 1991, 164 (1 Pt 1): 141-6[Crossref]
  • 65. Eronen M.: The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study. Pediatr Res 1993, 33 (6): 615-9[Crossref]
  • 66. Harlass FE, et al.: Hydrops fetalis and premature closure of the ductus arteriosus: a review. Obstet Gynecol Surv 1989, 44 (7): 541-3[Crossref]
  • 67. Fyfe DA and Kline DC.: Fetal echocardiographic diagnosis of congenital heart disease. Pediatr Clin North Am 1990, 37 (1): 45-67
  • 68. Momma K and Ando M.: In situ morphology of fetal aortic isthmus following ductal constriction in rats. Fetal Diagn Ther 1994, 9 (1): 53-61[Crossref]
  • 69. Levin DL, et al.: Fetal hypertension and the development of increased pulmonary vascular smooth muscle: a possible mechanism for persistent pulmonary hypertension of the newborn infant. J Pediatr 1978, 92 (2): 265-9[Crossref]
  • 70. Levin DL, Mills LJ and Weinberg AG.: Hemodynamic, pulmonary vascular, and myocardial abnormalities secondary to pharmacologic constriction of the fetal ductus arteriosus. A possible mechanism for persistent pulmonary hypertension and transient tricuspid insufficiency in the newborn infant. Circulation 1979, 60 (2): 360-4[Crossref]
  • 71. Cassin S, et al.: Pulmonary and systemic vascular responses of perinatal goats to prostaglandins E1 and E2. Am J Physiol 1979, 236 (6): H828-32
  • 72. Starling MB and Elliott RB.: The effects of prostaglandins, prostaglandin inhibitors, and oxygen on the closure of the ductus arteriosus, pulmonary arteries and umbilical vessels in vitro. Prostaglandins 1974, 8 (3): 187-203[Crossref]
  • 73. Harada K, et al.: Doppler echocardiographic evaluation of ventricular diastolic filling in fetuses with ductal constriction. Am J Cardiol 1997, 79 (4): 442-6[Crossref]
  • 74. Murphy JD, et al.: The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 1981, 98 (6): 962-7[Crossref]
  • 75. Murphy JD, Vawter GF and Reid LM.: Pulmonary vascular disease in fatal meconium aspiration. J Pediatr 1984, 104 (5): 758-62[Crossref]
  • 76. Levin DL, et al.: Morphological development of the pulmonary vascular bed in fetal lambs. Circulation 1976, 53 (1): 144-51[Crossref]
  • 77. Macones GA and Robinson CA.: Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol 1997, 177 (4): 819-24[Crossref]
  • 78. Hofstadler G, et al.: Spontaneous closure of the human fetal ductus arteriosus--A cause of fetal congestive heart failure. Am J Obstet Gynecol 1996, 174 (3): 879-83[Crossref]
  • 79. Harada K, et al.: Two-dimensional echocardiographic evaluation of ventricular systolic function in human fetuses with ductal constriction. Ultrasound Obstet Gynecol 1997, 10 (4): 247-53[Crossref]
  • 80. Huhta JC, et al.: Detection and quantitation of constriction of the fetal ductus arteriosus by Doppler echocardiography. Circulation 1987, 75 (2): 406-12[Crossref]
  • 81. Zielinsky P, et al.: Reversal of fetal ductal constriction after maternal restriction of polyphenol-rich foods: an open clinical trial. J Perinatol 2012, 32 (8): 574-9[Crossref]
  • 82. Mielke G and Benda N.: Reference ranges for two-dimensional echocardiographic examination of the fetal ductus arteriosus. Ultrasound Obstet Gynecol 2000, 15 (3) : 219-225[Crossref]
  • 83. Tulzer G, et al.: Doppler echocardiography of fetal ductus arteriosus constriction versus increased right ventricular output. J Am Coll Cardiol 1991, 18 (2): 532-6[Crossref]
  • 84. Van den Hoff MJ, et al.: Increased cardiac workload by closure of the ductus arteriosus leads to hypertrophy and apoptosis rather than to hyperplasia in the late fetal period. Naunyn Schmiedebergs Arch Pharmacol 2004, 370 (3): 193-202
  • 85. Mori Y, et al.: Evaluation of systolic and diastolic ventricular performance of the right ventricle in fetuses with ductal constriction using the Doppler Tei index. Am J Cardiol, 2001. 88(10): 1173-8[Crossref]
  • 86. Mari, G., et al.: Doppler assessment of the pulsatility index of the middle cerebral artery during constriction of the fetal ductus arteriosus after indomethacin therapy. Am J Obstet Gynecol, 1989. 161(6 Pt 1): 1528-31[Crossref]
  • 87. Respondek M, Weil SR and Huhta JC.: Fetal echocardiography during indomethacin treatment. Ultrasound Obstet Gynecol 1995, 5 (2): 86-9[Crossref]
  • 88. Rudolph AM.: The effects of nonsteroidal antiinflammatory compounds on fetal circulation and pulmonary function. Obstet Gynecol 1981, 58(5Suppl): 63S-7S
  • 89. Coceani F.: Control mechanisms for the ductus arteriosus and the perinatal pulmonary circulation. J Lipid Mediat 1993, 6 (1-3): 473-6
  • 90. Van Marter LJ, et al.: Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics, 1996, 97 (5): 658-63
  • 91. Abman, SH.: Abnormal vasoreactivity in the pathophysiology of persistent pulmonary hypertension of the newborn. Pediatr Rev 1999, 20 (11): e103-9
  • 92. Walsh-Sukys MC.: Persistent pulmonary hypertension of the newborn.The black box revisited. Clin Perinatol 1993, 20 (1): 127-43
  • 93. Manchester D, Margolis HS and Sheldon RE.: Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 1976, 126 (4): 467-9
  • 94. Csaba IF, Sulyok E and Ertl T.: Relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome. J Pediatr 1978, 92 (3): 484[Crossref]
  • 95. Goudie BM and Dossetor JF.: Effect on the fetus of indomethacin given to suppress labour. Lancet 1979, 2 (8153): 1187-8[Crossref]
  • 96. Rubaltelli FF, et al.: Effect on neonate of maternal treatment with indomethacin. J Pediatr 1979, 94 (1): 161[Crossref]
  • 97. Besinger RE. et al.: Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991, 164 (4): 981-6 discussion 986-8[Crossref]
  • 98. Wilkinson AR, Aynsley-Green A and Mitchell MD: Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen. Arch Dis Child 1979, 54 (12): 942-5[Crossref]
  • 99. Turner GR and Levin DL.: Prostaglandin synthesis inhibition in persistent pulmonary hypertension of the newborn. Clin Perinatol 1984, 11(3): 581-9
  • 100. Norton ME, et al.: Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993, 329 (22): 1602-7
  • 101. Alano MA, et al.: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn.Pediatrics 2001, 107 (3): 519-23[Crossref]
  • 102. Hernández-Díaz S, et. al: Risk factors for persistent pulmonary hypertension of the newborn. Pedatrics 2007, 120:e272[Crossref]
  • 103. Van Marter LJ. et al.: Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics 2013, 131 (1): 79-87
  • 104. Heymann MA and Rudolph AM.: Effects of acetylsalicylic acid on the ductus arteriosus and circulation in fetal lambs in utero. Circ Res 1976, 38 (5): 418-22[Crossref]
  • 105. Levin DL, et al.: Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 1978, 92 (3): 478-83[Crossref]
  • 106. Lock JE, et al.: Indomethacin-induced pulmonary vasoconstriction in the conscious newborn lamb. Am J Physiol 1980, 238 (5): H639-51
  • 107. Velioglu YS, et al.: Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. Journal of Agricultural and Food Chemistry 1998, 46:4113-4117[Crossref]
  • 108. Bravo L.: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998, 56 (11): 317-33
  • 109. Scalbert A and Williamson G.: Dietary intake and bioavailability of polyphenols. J Nutr 2000, 130(8S Suppl): 2073S-85S
  • 110. Majewska M, et al.: Evaluation of antioxidant potential of flavonoids: an in vitro study. Acta Pol Pharm 2011, 68(4): 611-5
  • 111. Fukumoto LR and Mazza G.: Assessing antioxidant and prooxidant activities of phenolic compounds. J Agric Food Chem 2000, 48 (8): 3597-604 [Crossref]
  • 112. Nijveldt RJ, et al.: Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001, 74 (4): 418-25
  • 113. USDA, Database for the Flavonoid Content of Selected Foods Release
  • 114. http://www.nal.usda.gov/fnic/foodcomp/Data/Flav/Flav02-1.pdf, 2007
  • 115. Heijnen CG, et al.: Peroxynitrite scavenging of flavonoids: structure activity relations. Environ Toxicol Pharmacol 2001, 10 (4): 199-206[Crossref]
  • 116. Chun OK, Kim DO and Lee CY.: Superoxide radical scavenging activity of the major polyphenols in fresh plums. J Agric Food Chem 2003, 51 (27): 8067-72[Crossref]
  • 117. Akkol EK, et al.: The treatment of inflammation, pain, and Fever using medicinal plants. Adv Pharmacol Sci 2012, 2012: 476985
  • 118. Chen B, et al.: Pomegranate juice and punicalagin attenuate oxidative stress and apoptosis in human placenta and in human placental trophoblasts. Am J Physiol Endocrinol Metab 2012, 302 (9): E1142-52[Crossref]
  • 119. Andujar I, et al.: Cocoa polyphenols and their potential benefits for human health. Oxid Med Cell Longev 2012, 2012: 906252
  • 120. Mathew AS, et al.: Acute effects of pomegranate extract on postprandial lipaemia, vascular function and blood pressure. Plant Foods Hum Nutr 2012, 67 (4): 351-7[Crossref]
  • 121. Hodgson JM, et al.: Black tea lowers the rate of blood pressure variation: a randomized controlled trial. Am J Clin Nutr 2013, 97 (5): 943-50[Crossref]
  • 122. Hodgson JM, et al.: Short-term effects of polyphenol-rich black tea on blood pressure in men and women. Food Funct 2013, 4 (1): 111-5[Crossref]
  • 123. D’Argenio G, et al.: Apple polyphenol extracts prevent aspirin-induced damage to the rat gastric mucosa. Br J Nutr 2008, 100 (6): 1228-36[Crossref]
  • 124. Khan HY, et al.: A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. Curr Drug Targets 2012, 13 (14): 1738-49[Crossref]
  • 125. Hadi SM, et al.: Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol 2007, 17 (5): 370-6[Crossref]
  • 126. Malik A, et al.: DNA degradation by water extract of green tea in the presence of copper ions: implications for anticancer properties. Phytother Res 2003, 17 (4): 358-63[Crossref]
  • 127. Widmer RJ, et al.: Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. Eur J Nutr 2013, 52 (3): 1223-31[Crossref]
  • 128. Romain C, et al.: Vineatrol and cardiovascular disease: beneficial effects of a vine-shoot phenolic extract in a hamster atherosclerosis model. J Agric Food Chem 2012, 60 (44): 11029-36[Crossref]
  • 129. Andrade JP and Assuncao M.: Protective effects of chronic green tea consumption on age-related neurodegeneration. Curr Pharm Des 2012, 18 (1): 4-14[Crossref]
  • 130. Valls-Pedret C, et al.: Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk. J Alzheimers Dis 2012, 29 (4): 773-82
  • 131. Kupeli E, et al.: Estimation of antinociceptive and anti-inflammatory activity on Geranium pratense subsfinitimum and its phenolic compounds. J Ethnopharmacol 2007, 114 (2): 234-40[Crossref]
  • 132. Kupeli E, et al.: Bioassay-guided isolation of anti-inflammatory and antinociceptive glycoterpenoids from the flowers of Verbascum lasianthum Boiss. ex Bentham. J Ethnopharmacol 2007, 110 (3): 444-50[Crossref]
  • 133. Lorenzi HM, FJA.: Plantas medicinais no Brasil: nativas e exóticas. Nova Odessa: Instituto Plantarum de Estudo da Flora 2002: 512
  • 134. Chen PC, et al.: A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 2002, 26 (5): 233-41[Crossref]
  • 135. Di Paola R, et al.: Green tea polyphenol extract attenuates lung injury in experimental model of carrageenan-induced pleurisy in mice. Respir Res 2005, 6: 66
  • 136. Smith DM and Dou QO.: Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med 2001, 7 (6): 645-52
  • 137. Zhang G, Miura Y and Yagasaki K.: Suppression of adhesion and invasion of hepatoma cells in culture by tea compounds through antioxidative activity. Cancer Lett 2000, 159(2): 169-73[Crossref]
  • 138. Duffy SJ, et al.: Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001, 104 (2): 151-6[Crossref]
  • 139. Duffy SJ, et al.: Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21(6): 1084-9[Crossref]
  • 140. Kris-Etherton PM, et al.: Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002, 113 Suppl 9B: 71S-88S
  • 141. Martinez J and Moreno JJ.: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000, 59 (7): 865-70[Crossref]
  • 142. Subbaramaiah K, et al.: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998, 273 (34): 21875-82[Crossref]
  • 143. Bixby M, et al.: Ilex paraguariensis extracts are potent inhibitors of nitrosative stress: a comparative study with green tea and wines using a protein nitration model and mammalian cell cytotoxicity. Life Sci 2005, 77 (3): 345-58[Crossref]
  • 144. Ito H, et al.: Polyphenol levels in human urine after intake of six different polyphenol-rich beverages. Br J Nutr 2005, 94 (4): 500-9[Crossref]
  • 145. Di Giuseppe R, et.al.: Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. The Journal of Nutrition 2008, 138:1939-1945
  • 146. Selmi C, et al.: Chocolate at heart: the anti-inflammatory impact of cocoa flavanols. Mol Nutr Food Res 2008, 52 (11): 1340-8[Crossref]
  • 147. Backhouse N, et al.: Anti-inflammatory and antipyretic effects of boldine. Agents Actions 1994, 42 (3-4): 114-7[Crossref]
  • 148. Khayyal MT, et al.: A clinical pharmacological study of the potential beneficial effects of a propolis food product as an adjuvant in asthmatic patients. Fundam Clin Pharmacol 2003. 17 (1): 93-102[Crossref]
  • 149. Silva JR, et al.: Extract of Passiflora edulis in the healing process of gastric sutures in rats: a morphological and tensiometric study. Acta Cir Bras 2006, 21 Suppl 2: 52-60
  • 150. Montanher AB, et al.: Evidence of anti-inflammatory effects of Passiflora edulis in an inflammation model. J Ethnopharmacol 2007, 109 (2): 281-8[Crossref]
  • 151. Jin UH, et al.: Inhibitory effect of Panax notoginseng on nitric oxide synthase, cyclo-oxygenase-2 and neutrophil functions. Phytother Res 2007, 21 (2): 142-8[Crossref]
  • 152. Bozin B, et al.: Antimicrobial and antioxidant properties of rosemary and sage (Rosmarinus officinalis L. and Salvia officinalis L., Lamiaceae) essential oils. J Agric Food Chem 2007, 55 (19): 7879-85[Crossref]
  • 153. Celik I and Isik I.: Determination of chemopreventive role of Foeniculum vulgare and Salvia officinalis infusion on trichloroacetic acid-induced increased serum marker enzymes lipid peroxidation and antioxidative defense systems in rats. Nat Prod Res 2008, 22 (1): 66-75[Crossref]
  • 154. Della Loggia R, et al.: The role of flavonoids in the antiinflammatory activity of Chamomilla recutita. Prog Clin Biol Res 1986, 213: 481-4
  • 155. Pozharitskaya ON, et al.: Separation and evaluation of free radicalscavenging activity of phenol components of green, brown, and black leaves of Bergenia crassifolia by using HPTLC-DPPH* method. J Sep Sci 2007, 30 (15): 2447-51[Crossref]
  • 156. Pozharitskaya ON, et al.: Separation and evaluation of free radicalscavenging activity of phenol components of Emblica officinalis extract by using an HPTLC-DPPH* method. J Sep Sci 2007, 30 (9): 1250-4[Crossref]
  • 157. Zielinsky P, et al.: Maternal restriction of polyphenols and fetal ductal dynamics in normal pregnancy: an open clinical trial. Arq Bras Cardiol 2013, 101 (3): 217-225
  • 158. Zielinsky P, et al.: Maternal consumption of polyphenol-rich foods in late pregnancy and fetal ductus arteriosus flow dynamics. J Perinatol 2010, 30 (1): 17-21[Crossref]
  • 159. Zielinsky P, et al.: New insights on fetal ductal constriction: role of maternal ingestion of polyphenol-rich foods. Expert Rev Cardiovasc Ther 2010, 8 (2): 291-8 [Crossref]
  • 160. Zielinsky, P, et al.: Fetal ductal constriction caused by maternal ingestion of green tea in late pregnancy: an experimental study. Prenat Diagn 2012, 32 (10): 921-6[Crossref]
  • 161. Vian I, et al.: Development and validation of a food frequency questionnaire for consumption of polyphenol-rich foods in pregnant women. Matern Child Nutr 2013 DOI10.III/mcn.I 2025
  • 162. Kapadia V, et al.: Prenatal closure of the ductus arteriosus and maternal ingestion of anthocyanins. J Perinatol 2010, 30 (4): 291-4[Crossref]
  • 163. Sridharan S, Archer N and Manning N.: Premature constriction of the fetal ductus arteriosus following the maternal consumption of camomile herbal tea. Ultrasound Obstet Gynecol 2009, 34 (3): 358-9[Crossref]
  • 164. Zielinsky P, et al.: Experimental study of the role of maternal consumption of green tea, mate tea and grape juice on fetal ductal constriction. 17th World Congress on Ultrasound in Obstetrics and Gynecology 2007,Ultrasound in Obstetrics and Gynecology 2007, 30: 515
  • 165. Bubols GB, et al.: Nitric oxide and reactive species are modulated in the polyphonol-induced ductus arteriosus constriction in pregnant sheep. Prenat Diagn 2014, doi: 10.1002/pd.4463[Crossref]
  • 166. Zielinsky P, et al.: Experimental Assessment of Ductus Arteriosus Flow, Oxidative Stress and Polyphenol Excretion After Maternal Polyphenol-Rich Diet in Late Pregnancy. 22nd World Congress on Ultrasound in Obstetrics and Gynecology, 2012, Copenhagen - Ultrasound in Obstetrics and Gynecology 2012, 40: 16
  • 167. Mercanti I, et al.: Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know. Curr Pharm Des 2012, 18 (21): 3007-18[Crossref]
  • 168. Shima Y, et al.: Idiopathic severe constriction of the fetal ductus arteriosus: a possible underestimated pathophysiology. Eur J Pediatr 2011, 170 (2): 237-40[Crossref]
  • 169. Enzensberger C, et al.: Idiopathic constriction of the fetal ductus arteriosus: three cases and review of the literature. J Ultrasound Med 2012, 31 (8): 1285-91
  • 170. Tanaka M, et al.: Functional foods for the fetus? Acta Obstet Gynecol Scand 2011, 90(10): 1172-3[Crossref]
  • 171. Sheehan M, et al.: Position statement on ethics, equipoise and research on charged particle radiation therapy. J Med Ethics, 2013
  • 172. Petticrew M, et al.: In search of social equipoise. BMJ 2013, 347: f4016
  • 173. Freedman B.: Equipoise and the ethics of clinical research. N Engl J Med 1987, 317 (3): 141-5[Crossref]
  • 174. Hellman S and Hellman DS.: Of mice but not men. Problems of the randomized clinical trial. N Engl J Med 1991, 324 (22): 1585-9
  • 175. Joffe S and Miller FG.: Equipoise: asking the right questions for clinical trial design. Nat Rev Clin Oncol 2012, 9 (4): 230-5[Crossref]
  • 176. Adibe OO and Peter SD.: Equipoise, ethics, and the necessity of randomized trials in surgery. Arch Surg 2012, 147 (10): 899-900[Crossref]
  • 177. Gifford F.: Pulling the plug on clinical equipoise: a critique of Miller and Weijer. Kennedy Inst Ethics J 2007, 17 (3): 203-26; discussion 227-46 [Crossref]
  • 178. Van der Graaf R.: On what we will lose in giving up on clinical equipoise: A reply to Miller. Clinical Trials, 2012
  • 179. Van der Graaf R.: Equipoise should be amended, not abandoned. Clinical Trials, 2011
  • 180. Zielinsky P and Busato S.: Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus. Birth Defects Research (Part C) 2013. 99: 256-74

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.